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Primary vaginal cancer is a rare gynecological ma-lignancy, constituting only 1% to 2% of all gyne-cological cancers.1 The majority of vaginal cancers 
are squamous cell carcinoma (SCC); other types include 
adenocarcinoma, melanomas and sarcomas. Most vagi-
nal SCC are believed to develop from pre-cancerous vag-
inal intraepithelial neoplasia. SCC usually involves the 
posterior wall of the upper-third of the vagina and may 
directly invade the bladder or rectum. It initially spreads 
superficially within the vaginal wall and later invades the 
paravaginal tissues. Distant metastases occur commonly 
to lungs and liver. Prognosis depends primarily on the 
stage of disease. Mardsen et al reported 5-year survival 
rate of stage I, II, III, IV disease as 69%, 48%, 33% and 
18%, respectively.2 The survival rate of stage IVB vaginal 
cancer in particular, is not clearly documented, consider-
ing the rarity of the disease. We document a sustained 
complete remission with a taxane-based chemotherapy 
in stage IVB primary vaginal SCC. 
CASE 
A 58-year-old postmenopausal woman presented in July 
2004 with irregular vaginal bleeding for the previous 6 
weeks. She also complained of progressively increasing 
drowsiness, constipation and acute retention of urine 
for the last 2 days. She became sexually active at the age 
of 18 years and gave no history of multiple sexual part-
ners. There was no history of exposure to diethylstilbes-
trol during her fetal life and she had never used vaginal 
pessaries. She was a non-smoker, non-alcoholic and had 
no history of chronic steroid use. On examination, the 
patient was drowsy and incoherent, but arousable on 
command with no focal neurological deficit. There was 
no lymphadenopathy. Gynecological examination per 
speculum revealed a thickened, inflamed vagina until 
the introitus with ulcerative areas. There were multiple, 
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irregular, pea-sized nodular growths on the anterior 
vaginal wall more than the posterior, which easily bled 
in response to touch. On pelvic examination, the uterus 
and cervix were normal in size and free. Rectal examina-
tion revealed a smooth and free rectal mucosa. 
Pap smear showed non-specific inflammation and 
no evidence of infection with HPV. Histopathological 
examination of the vaginal tissue revealed poorly dif-
ferentiated SCC. Her blood parameters were normal 
except for serum calcium (3.1 mmol/L). MRI of the 
abdomen and pelvis showed abnormal thickening 
along the anterior vaginal wall, with extension into the 
bladder base, peri-urethral region, inferior retropubic 
region, vulval soft tissues and also into the perineum. 
CT chest demonstrated numerous small nodules scat-
tered in both lungs, with thickening of the interlobular 
septa (Figure 1). Imaging-guided fine needle aspira-
tory cytolog of the left lung was positive for malignant 
cells. The radionuclide bones scan showed increased 
tracer uptake in the bilateral superior pubic rami, the 
left pubic bone at the symphysis pubis and the shaft of 
the right fibula. The case was thus diagnosed as carci-
noma of the vagina stage IVB disease (spread outside 
pelvic area; according to the FIGO & TNM classifi-
cation) with metastasis to the regional lymph nodes, 
lung and bone, with hypercalcemia and metabolic en-
cephalopathy.3,4 In view of her extensive disease, she 
was started on a 3 weekly chemotherapy of paclitaxel 
(175 mg/m2) day 1; and cisplatin (30 mg/m2), leu-
covorin (30 mg), fluorouracil (5-FU) (500 mg/m2) 
days 1 to 3. She was also given xolendronic acid (4 
mg) monthly. The patient showed improvement in her 
serum calcium levels and sensorium within 3 days of 
instituting chemotherapy. She had improvement in 
her vaginal symptoms and her urinary catheter could 
be removed. The patient could complete such six cy-
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cles of chemotherapy. Investigations undertaken after 
chemotherapy in January 2005, showed complete re-
mission (CR). CT abdomen showed complete reso-
lution of the original mass lesion in relation to the 
vagina and CT chest showed well-aerated lungs with 
absence of any focal metastatic nodule. Pelvic exami-
nation revealed the vagina to be smooth and clear of 
the nodular lesions. The cervix and uterus were nor-
mal in size and free. The patient was advised to have 
a regular follow-up with pelvic examination, MRI 
whole abdomen and pelvis, CT chest and biochemical 
profile every 6 months. MRI of the pelvis in February 
2007 showed sustained CR (Figure 2). The patient 
has continued to maintain CR for over 40 months, 
since the initial response.
DISCUSSION
For patients with early stage vaginal carcinoma, the 
standard treatment is highly effective. However, there 
is no consensus as to the appropriate management of 
advanced stage vaginal cancer. As primary advanced 
stage vaginal cancers are rare, there are a few anecdotal 
reports that document the efficacy of chemotherapy 
in the treatment of the disease. Thigpen made one of 
the earliest attempts in 1986 in which 26 patients with 
advanced or recurrent carcinoma of the vagina were 
subjected to a regimen of cisplatin (50 mg/m2) every 
3 weeks.5 One patient had CR (6.2%), 5 patients had 
stable disease and 10 patients had progressive disease, 
among the 16 evaluable patients with SCC. Muss 
documented no responses among 19 evaluable patients 
treated with mitoxantrone.6 In the study by Long et al,3 
patients with advanced vaginal SCC received treatment 
with methotrexate, vinblastine, doxorubicin and cispla-
tin, and achieved CR of short duration.7 Umesaki et al 
reported a case of stage II vaginal cancer that showed 
CR after chemotherapy with irinotecan and cisplatin.8 
Katib et al reported CR using a multidrug treatment 
of bleomycin, methotrexate, and cisplatin in a case of 
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Figure 1. Disease status at the time of diagnosis. Vaginal cancer (left), pulmonary 
metastases (right).
Figure 2. Disease status after 40 months of treatment. Vaginal cancer (left), pulmonary 
metastases (right).
advanced vaginal carcinoma.9 
Taxane-based protocols are widely used in SCC of 
other sites including the cervix, lung, head and neck, 
and stomach. With this background, we started our pa-
tient on chemotherapy protocol consisting of paclitaxel, 
cisplatin and 5-FU. Our patient achieved CR post-6 
cycles and continued to maintain remission for over 40 
months. Our case is the first reported case where sus-
tained CR has been observed with a taxane-based che-
motherapy in stage IVB vaginal cancer. 
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